Pfizer/Sanofi-Aventis/Nektar's Inhaled Insulin Exubera and Merck/Bristol             Myers' Squibb's Dual-Acting PPAR Agonist Pargluva  

Donny Wong Ph.D., analyst at Decision Resources, is available to discuss the impact of the FDA advisory committee's recommendation to approve Exubera, the first inhaled insulin product to treat Type 2 Diabetes and Pargluva (muraglitazar) the first dual-acting PPAR agonist to treat Type 2 Diabetes.

Dr. Wong has just recently completed a report on the type 2 diabetes market and can share:

  * Role of these agents in medical practice and unmet needs that they will     address   * Market forecasts for these two drugs and other novel agents in     development   * Explanation of concerns over long-term safety of these two drugs   * Impact on the insulin market once the first inhaled product is available  

Donny Wong, Ph.D., is a research analyst in the Metabolic Diseases group at Decision Resources, where his work has focused on obesity, type 2 diabetes, and metabolic syndrome. Dr. Wong has over 12 years of experience in scientific research and has co-authored several peer-reviewed articles and reviews. Dr. Wong attended MIT and Williams College and earned M.M.Sc. and Ph.D. degrees from Harvard University.

To speak with Dr. Wong, please contact Liz Marshall at Decision Resources at 781-296-2563 or emarshall@dresources.com.

About Decision Resources

Decision Resources (http://www.decisionresources.com/) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

PRNewswire -- Sept. 13

SOURCE: Decision Resources

CIGNA Increases Healthcare Market Share in Tennessee, According to HealthLeaders-InterStudy

View Now